FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy I... (onments it gives radiation oncologiststh...)

FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications

Date:3/17/2008

onments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently.

In its current use for the treatment of early stage breast cancer, the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

"The expanded clearance for the Axxent Controller is very significant in that it validates that the FDA recognizes Electronic Brachytherapy is a platform technology that is viable for treatment of conditions outside of the breast," said Michael Klein, president and CEO of Xoft. "This serves as the foundation for Xoft's expansion into new treatment areas beyond breast cancer and fuels the continued market adoption and expansion of this important technology."

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.

0

GOOD

Page: 1 2
Related biology technology :

1. New filter clears up fiber optic communications
2. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
3. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
4. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
8. HOYA ConBio and The Hornbrook Group Announce Expanded Alliance
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
11. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated

Post Your Comments:

FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy I...(onments it gives radiation oncologiststh...)